Antibody-Drug Conjugates (ADC) Patent Landscape 2026
Antibody-Drug Conjugates (ADC) Patent Landscape in 2026
The ADC patent field is concentrated at the top — Genentech leads by a wide margin, with the top five filers holding one-third of the largest hundred filers’ combined output — while the field continues to expand on a multi-year basis, though annual volume has eased from its 2023 peak. Medicinal preparations and peptide/protein chemistry dominate the technology mix, with adjacent branches in heterocyclic compound chemistry and genetic engineering remaining comparatively under-served.
Genentech leads a concentrated but broadly contested ADC field
Genentech holds the leading position with 9,593 patent records, more than twice the count of the second-ranked applicant, Regeneron Pharmaceuticals at 4,956 patent records. F. Hoffmann-La Roche rounds out the top three at 4,623 patent records, reinforcing Roche Group’s combined dominance at the top tier.
The top five filers — Genentech, Regeneron, F. Hoffmann-La Roche, Seagen, and Daiichi Sankyo — collectively account for 33% of the hundred largest filers’ combined total, signaling meaningful concentration at the apex while leaving a substantial competitive layer below, including Novartis, ImmunoGen, Bristol Myers Squibb, MedImmune, and Immunomedics each with over 1,600 patent records.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Genentech Inc | 9,593 | |
| 2 | Regeneron Pharmaceuticals Inc | 4,956 | |
| 3 | F HOFFMANN LA ROCHE & CO AG | 4,623 | |
| 4 | Seagen Inc | 2,741 | |
| 5 | Daiichi Sankyo Co Ltd | 2,728 | |
| 6 | Novartis AG | 2,560 | |
| 7 | ImmunoGen Inc | 1,796 | |
| 8 | Bristol Myers Squibb Co | 1,773 | |
| 9 | MedImmune Ltd | 1,730 | |
| 10 | Immunomedics Inc | 1,605 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | AbbVie Inc | 1,390 | |
| 12 | Chugai Pharmaceutical Co Ltd | 1,274 | |
| 13 | Regents of the University of California | 1,234 | |
| 14 | Pfizer Inc | 1,209 | |
| 15 | U.S. Government (as represented by the Secretary of Health and Human Services) | 1,142 | |
| 16 | Board of Regents, The University of Texas System | 1,034 | |
| 17 | Janssen Biotech Inc | 942 | |
| 18 | Pierre Fabre Medicament SAS | 930 | |
| 19 | F. Hoffmann-La Roche Inc | 906 | |
| 20 | Sanofi SA | 904 |
The scale of Genentech’s and Roche’s positions, together with the breadth of the second tier, indicates that large pharma incumbents have built deep defensive and offensive portfolios. Challengers such as Daiichi Sankyo and Seagen have established significant footholds, particularly in conjugate chemistry and therapeutic activity, reflecting their commercial ADC programmes.
Filing counts for 2024 and 2025 are materially understated due to standard patent publication lag; apparent softening in those years should not be read as a reversal of the multi-year growth trend. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Sustained multi-year growth with medicinal-preparation chemistry at the core
Annual filing data show a consistent upward trajectory from 2017 through 2023, with the technology composition dominated by medicinal preparations and peptide/protein classes. Both charts together reveal a maturing but still-active field where the core IPC classes are densely covered and several adjacent branches remain comparatively sparse.
Annual filing trend
Filings rose from 1,245 records in 2017 to a peak of 1,987 in 2023, representing a 15% gain in the most recent measured multi-year window. The apparent drop in 2024 and near-absence in 2025–2026 reflect publication lag rather than a real decline; those years are substantially under-counted and should be interpreted with caution.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61K (medicinal preparations) and C07K (peptides and proteins) together account for the two largest shares of IPC-level records, followed closely by A61P (therapeutic activity). Microorganism and genetic engineering (C12N), material analysis (G01N), and heterocyclic compounds (C07D) form a meaningful secondary tier but are proportionally sparse relative to the core trio, signalling where coverage thins.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
SG158400B
[0001] This non-provisional application filed under 37 CFR §I 53(b), claims the benefit under 35 USC §119( e) of U.S. Provisional Application Serial No. 60!950,052 filed on July 16, 2007, U.S. Provisional Application Serial No. 61/025,137 filed on January 31, 2008, U.S. Provisional Application Serial No. 611032, 790 filed on February 29, 2008, and U.S… (excerpt from the patent abstract)
Open this patent in Eureka →| # | Patent | Citations |
|---|---|---|
| 1 | Cysteine engineered antibodies and conjugates | 3,799 |
| 2 | Monomethylvaline compounds capable of conjugation … | 2,728 |
| 3 | Thioether conjugates | 1,717 |
| 4 | Monomethylvaline compounds capable of conjugation … | 1,641 |
| 5 | Cysteine engineered antibodies and conjugates | 1,095 |
| 6 | Human antibodies that bind lymphocyte activation g… | 913 |
| 7 | Monomethylvaline compounds capable of conjugation … | 852 |
| 8 | Pyrrolobenzodiazepines and conjugates thereof | 844 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents.
What the ADC patent structure means for R&D investment
The combination of a concentrated leader tier, a broad second tier, active jurisdictional coverage, and identifiable sparse branches provides actionable signals for both incumbents and new entrants evaluating where to direct ADC research resources.
Growth stage — expanding on a multi-year basis, annual volume easing from 2023 peak
The field sits in a Growth lifecycle stage: recent three-year filing volume sits well above the prior three-year window, confirming continued expansion. Annual counts peaked in 2023 at 1,987 records and have eased since, though publication lag accounts for much of the apparent 2024–2025 softening. For R&D planners, this means core mechanism claims are being filed rapidly and freedom-to-operate analysis is increasingly essential for new entrants.
Growth · post-peak annual volumeTop five hold one-third of the largest hundred filers’ output — second tier is broad
With the top five filers holding 33% of the top-100 combined patent records and ten applicants each exceeding 1,200 records, the ADC field is concentrated at the top but not a duopoly. The second tier — spanning Novartis, ImmunoGen, Bristol Myers Squibb, MedImmune, Immunomedics, AbbVie, Chugai, and the Regents of UC — indicates that a diverse set of large-cap players have built defensible positions. New entrants face a dense prior-art landscape in core conjugate chemistry but may find differentiation space in adjacent branches.
High concentration · broad second tierCo-applicant filing data not available in current evidence set
Structured co-applicant collaboration data are not available in the current evidence set, so a quantitative read on cross-institutional co-filing patterns cannot be provided. Qualitatively, the presence of academic applicants — including the Regents of UC, the University of Texas System, and several European research institutes — alongside large pharma applicants suggests an ecosystem with active industry-academia transfer, but the volume and directionality of formal co-filings require further analysis.
Evidence pendingUS leads filing jurisdictions; PCT and EPO routes confirm global commercial intent
The United States is the leading jurisdiction with 5,700 patent records, followed by the EPO at 4,027 and WIPO PCT at 3,303, indicating that leading filers are pursuing broad multi-jurisdictional protection as a standard practice. Australia and Canada also appear as significant secondary markets. The relatively limited presence in the United Kingdom as a standalone jurisdiction, and in South Africa, suggests uneven geographic coverage that smaller players or generics developers may monitor for market entry.
US-led · broad PCT coverageGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
Co-filing pairs, ranked by the number of jointly-filed patent families.
Genentech leads on antibody engineering; Daiichi Sankyo distinguishes itself on conjugate-chemistry emphasis
Applicant-level technology focus data show that while most leading filers share coverage across C07K (antibody/protein engineering) and A61K (medicinal preparations), Daiichi Sankyo is notably weighted toward A61K47 (conjugate-specific medicinal preparations) and A61K31 (small-molecule preparations), reflecting its linker-payload differentiation strategy. Applicant momentum data are not available in the current evidence set, so trajectory reads below are drawn from technology focus profiles and ranking position.
Genentech Inc
Genentech holds the top position with 9,593 patent records, a count more than double that of the second-ranked applicant. Its technology focus centres on C07K16 (antibody engineering, 1,459 records), A61K39 (immunological preparations, 1,109 records), and A61P35 (anti-tumour therapeutic activity, 1,077 records), consistent with a broad-spectrum ADC portfolio anchored in antibody-targeting and oncology indication claims. Applicant momentum data are not available; the scale of the existing portfolio implies substantial prior-art density in core antibody-targeting mechanisms.
patent records: 9,593Daiichi Sankyo Co Ltd
Daiichi Sankyo ranks fifth overall with 2,728 patent records and presents a notably different technology emphasis from the Roche/Genentech cluster: its focus leads with A61K47 (conjugate-carrier medicinal preparations, 587 records), A61P35 (anti-tumour activity, 550 records), and A61K31 (small-molecule medicinal preparations, 470 records), reflecting investment in linker-payload chemistry rather than pure antibody engineering. This positioning aligns with the commercial profile of its trastuzumab deruxtecan platform. Applicant momentum data are not available in the current evidence set.
patent records: 2,728Under-served adjacent branches in genetic engineering and heterocyclic payload chemistry
Several IPC branches appear at materially lower density relative to the core medicinal-preparation and antibody-engineering classes. Three branches — C12N, C07D, and C12P — combine lower filing share with plausible technical relevance to next-generation ADC design, warranting closer examination by R&D teams evaluating differentiation paths.
C07D · Heterocyclic compounds — payload chemistry under-served relative to core
Heterocyclic compounds (C07D) account for only about 3% of IPC-level records in this corpus despite being the chemical backbone of many ADC payloads, including pyrrolobenzodiazepines (PBDs) and camptothecin derivatives. The most-cited patent family in the corpus covers PBD conjugates, confirming technical relevance. Sparsity here likely reflects that most filers claim payloads through broader A61K or C07K routes rather than C07D-specific claims, potentially leaving narrower compound-level claims available. Teams with novel payload scaffolds may find differentiated filing positions in this branch.
Search this in Eureka →C12P · Fermentation and enzymatic synthesis — sparse coverage for bioconjugation process claims
Fermentation and enzymatic synthesis (C12P) represents only about 1% of IPC-level records in the corpus. Site-specific conjugation using engineered enzymes — such as transglutaminase-based or sortase-mediated ligation — is an active research direction for improving drug-antibody ratio homogeneity, a known ADC differentiator. The low C12P density suggests this process-chemistry angle is comparatively uncrowded. Entry would require technical capability in both biocatalysis and antibody engineering, but for organisations already active in bioconjugation manufacturing, targeted process claims in this branch represent a plausible and potentially defensible position.
Search this in Eureka →How leading ADC filers differ by technology route emphasis
Strength of each leader across the main technology routes.
| Player | C07K 16 · Peptides & proteins | A61K 47 · Medicinal preparations | A61P 35 · Therapeutic activity of compounds | A61K 39 · Medicinal preparations | A61K 31 · Medicinal preparations |
|---|---|---|---|---|---|
| Genentech Inc | Strong · 1,459 | Strong · 924 | Strong · 1,077 | Strong · 1,109 | Moderate · 357 |
| Seagen Inc | Strong · 788 | Strong · 787 | Strong · 568 | Strong · 584 | Moderate · 175 |
| Daiichi Sankyo Co Ltd | Strong · 440 | Strong · 587 | Strong · 550 | Strong · 384 | Strong · 470 |
| Regeneron Pharmaceuticals Inc | Strong · 430 | Strong · 415 | Strong · 277 | Moderate · 205 | Emerging · 77 |
| ImmunoGen Inc | Strong · 345 | Strong · 280 | Strong · 230 | Strong · 257 | Moderate · 77 |
| MedImmune Ltd | Strong · 194 | Strong · 381 | Strong · 302 | Absent | Moderate · 167 |
| Immunomedics Inc | Strong · 235 | Strong · 260 | Absent | Strong · 179 | Strong · 185 |
Frequently asked questions
The analysis covers 13,815 patent families. The corpus spans global filings and is the basis for lifecycle, technology composition, and jurisdiction analysis; the applicant ranking uses patent record counts, which can exceed the family total because a single family may be counted in multiple jurisdictions or under multiple IPC codes.
Genentech Inc leads with 9,593 patent records, more than twice the count of the second-ranked applicant, Regeneron Pharmaceuticals at 4,956 patent records. F. Hoffmann-La Roche & Co AG is third at 4,623 patent records, making the Roche Group the dominant combined force in the field.
The field is classified as Growth. Recent three-year filing volume sits well above the prior three-year window, confirming multi-year expansion. Annual volume peaked in 2023 at 1,987 records and has eased since; however, 2024 and 2025 counts are substantially understated by publication lag and should not be read as a real decline.
The United States leads with 5,700 patent records, followed by the EPO at 4,027, WIPO PCT at 3,303, Australia at 2,479, and Canada at 2,093. Singapore also exceeds 1,000 records. This distribution reflects the standard multi-jurisdictional protection strategy of large pharma filers.
The most-cited document covers cysteine-engineered antibodies and conjugates with 3,799 citations. Other heavily cited works include monomethylvaline compounds capable of conjugation (cited 2,728 and 1,641 times across related variants), thioether conjugates (1,717 citations), and pyrrolobenzodiazepines and conjugates (844 citations). These works cluster around linker chemistry, site-specific conjugation, and payload design — the mechanistic core of ADC construction.
The evidence identifies C12N (microorganisms and genetic engineering, 5% share), G01N (material analysis and testing, 4% share), C07D (heterocyclic compounds, 3% share), C12P (fermentation and enzymatic synthesis, 1% share), and C07H (sugars and nucleic acids, 1% share) as comparatively sparse relative to the dominant A61K, C07K, and A61P classes. C07D and C12P are particularly relevant for teams working on novel payload scaffolds or enzymatic site-specific conjugation processes.
Ready to map your own ADC patent landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.